Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
CD123-targeted CAR-NK by Chongqing Precision Biotech for Refractory Acute Myeloid Leukemia: Likelihood of Approval
CD123-targeted CAR-NK is under clinical development by Chongqing Precision Biotech and currently in Phase II for Refractory Acute Myeloid Leukemia....
Data Insights
CD123-targeted CAR-NK by Chongqing Precision Biotech for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
CD123-targeted CAR-NK is under clinical development by Chongqing Precision Biotech and currently in Phase II for Relapsed Acute Myeloid Leukemia....